Julia Lopez MP: written questions
135 published records · newest first.
Written questions
Drugs: USADepartment for Business and TradeTabled 4 Dec 2025AnsweredUIN 97256More
Question: To ask the Secretary of State for Business and Trade, what legal instrument establishes Most Favoured Nation mitigations in the deal with the US on pharmaceuticals.
Answer: We have secured the first and only deal with the US that delivers zero percent tariffs on pharmaceutical products – the lowest rate offered to any country.It delivers mitigations on the US’ ‘Most Favoured Nation’ policy and preferential terms for UK medte...
Answered 9 Dec 2025
Original Parliament recordDrugs: USADepartment for Business and TradeTabled 4 Dec 2025AnsweredUIN 97255More
Question: To ask the Secretary of State for Business and Trade, what the mitigations are under the US Most Favoured Nation drug pricing initiative as referred to in the UK-US Economic Prosperity Deal.
Answer: The US has committed to ensuring that access to medicines and launches of new innovative medicines in the UK are not inadvertently impacted by the US’s ‘Most Favoured Nation’ policy, thereby reducing the risk to the UK where the NHS has managed to secure ...
Answered 9 Dec 2025
Original Parliament recordDrugs: USADepartment for Business and TradeTabled 4 Dec 2025AnsweredUIN 97254More
Question: To ask the Secretary of State for Business and Trade, which Department is responsible for monitoring of pharmaceutical provisions within the UK-US Economic Prosperity Deal; and whether he plans to update Parliament on those provisions.
Answer: DBT Secretary of State made a written statement to Parliament on 2 December.This deal is the first and only agreement with the US that secures zero percent tariffs on pharmaceutical products – the lowest rate offered to any country. It delivers mitigation...
Answered 9 Dec 2025
Original Parliament recordNHS: DrugsDepartment of Health and Social CareTabled 4 Dec 2025AnsweredUIN 97253More
Question: To ask the Secretary of State for Health and Social Care, from which Department’s budget the additional NHS medicines spend following the UK-US Economic Prosperity Deal will be funded.
Answer: Every patient deserves access to the best possible treatment. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector.Costs will start smaller but will increase over time as the Nat...
Answered 17 Dec 2025
Original Parliament recordNHS: DrugsDepartment of Health and Social CareTabled 4 Dec 2025AnsweredUIN 97252More
Question: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the 25% net increase in prices for new medicines and the 15% VPAG repayment cap on annual NHS medicines spend.
Answer: Every patient deserves access to the best possible treatment. This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector.Costs will start smaller but will increase over time as the Nat...
Answered 17 Dec 2025
Original Parliament recordDigital Service ProvidersDepartment for Business and TradeTabled 25 Nov 2025AnsweredUIN 94367More
Question: To ask the Secretary of State for Business and Trade, what steps his Department is taking to increase interoperability and competitiveness in the domestic cloud market following recent widespread outages caused by dominant providers in the industry.
Answer: In July 2025, the Competition and Markets Authority (CMA) published its final report on the UK cloud market. The key recommendation was for the CMA Board to prioritise commencing investigations under the digital markets regime and to consider designating ...
Answered 1 Dec 2025
Original Parliament recordInternet: OutagesTreasuryTabled 25 Nov 2025AnsweredUIN 94366More
Question: To ask the Chancellor of the Exchequer, what estimate her Department has made of the cost to the economy of recent outages of large-scale cloud providers.
Answer: I refer the member to the answer given to UIN 92928 on 24 November 2025.
Answered 1 Dec 2025
Original Parliament recordDigital Service Providers: CompetitionDepartment for Science, Innovation and TechnologyTabled 25 Nov 2025AnsweredUIN 94365More
Question: To ask the Secretary of State for Science, Innovation and Technology, what assessment her Department has made of the level of systemic risk from reliance on two dominant cloud providers following recent outages.
Answer: I refer the honourable member to the answer given on 24 November to UIN 92927. The Department for Science, Innovation and Technology (DSIT) continues to monitor systemic risks to UK critical national infrastructure from reliance on cloud providers, includ...
Answered 2 Dec 2025
Original Parliament recordDigital Service Providers: CompetitionDepartment for Science, Innovation and TechnologyTabled 25 Nov 2025AnsweredUIN 94364More
Question: To ask the Secretary of State for Science, Innovation and Technology, what steps she is taking to help ease restrictive licensing practices in relation to software by large cloud providers to ensure that there is fair and open competition in the sector.
Answer: The Government is committed to supporting a competitive and innovative digital economy. This is why we prioritised the commencement and implementation of the Competition and Markets Authority’s (the CMA) new powers in digital markets. The CMA is independe...
Answered 2 Dec 2025
Original Parliament recordDigital Service Providers: CompetitionDepartment for Science, Innovation and TechnologyTabled 25 Nov 2025AnsweredUIN 94363More
Question: To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to help accelerate the process to designate cloud services with Digital Market Unit's Strategic Market Status to prevent anti-competitive practices i
Answer: The Competition and Markets Authority (the CMA) has completed three Strategic Market Status investigations this year. The CMA is independent of the Government and decisions on which markets to investigate are for its Board. The CMA has published guidance ...
Answered 2 Dec 2025
Original Parliament recordVisual Impairment: RehabilitationDepartment of Health and Social CareTabled 25 Nov 2025AnsweredUIN 94360More
Question: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to secure a sustainable future for the vision rehabilitation workforce.
Answer: We are progressing towards a National Care Service, and this includes expanding career opportunities through the Care Workforce Pathway, and investing £12 million in learning, development, and new qualifications. The Level 2 Adult Social Care Certificate ...
Answered 2 Dec 2025
Original Parliament recordVisual Impairment: RehabilitationDepartment of Health and Social CareTabled 25 Nov 2025AnsweredUIN 94359More
Question: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of (a) the effect of no national oversight relating to the quality of vision rehabilitation services for patients in England and (b) the experiences of those
Answer: Under the Care Act 2014, local authorities have the duty to shape their care market and to commission a range of high-quality, sustainable, and person-centred care and support services to meet the diverse needs of all local people. This includes encouragi...
Answered 2 Dec 2025
Original Parliament recordVisual Impairment: RehabilitationDepartment of Health and Social CareTabled 25 Nov 2025AnsweredUIN 94358More
Question: To ask the Secretary of State for Health and Social Care, if he will make an assessment of recent trends in the number of patients receiving timely access to vision rehabilitation services in line with industry best practice.
Answer: The Care Quality Commission (CQC) is now assessing how local authorities are meeting the full range of their duties under Part 1 of the Care Act 2014. These assessments identify local authorities’ strengths and areas for development, facilitating the shar...
Answered 2 Dec 2025
Original Parliament recordDrugs: VATTreasuryTabled 3 Nov 2025AnsweredUIN 87680More
Question: To ask the Chancellor of the Exchequer, whether she has made an assessment of the potential impact of introducing VAT to to medicines provided free under Early Access Medicines Scheme programmes on pharmaceutical companies.
Answer: I refer the honourable member to the answer that I gave to PQ UIN: 87051.
Answered 11 Nov 2025
Original Parliament recordDrugs: VATTreasuryTabled 31 Oct 2025AnsweredUIN 87052More
Question: To ask the Chancellor of the Exchequer, what assessment her (a) Department and (b) HMRC have conducted on the potential impact on clinical trial numbers from the introduction of VAT to medicines provided free under Early Access Medicines Scheme programmes
Answer: VAT is the UK’s second largest tax, forecast to raise £180 billion in 2025/26. Taxation is a vital source of revenue which helps to fund public services. Early Access to Medicines Scheme (EAMS) allows patients access to free medicines for life threatening...
Answered 5 Nov 2025
Original Parliament recordDrugs: VATTreasuryTabled 31 Oct 2025AnsweredUIN 87051More
Question: To ask the Chancellor of the Exchequer, what assessment (a) her Department and (b) HMRC have conducted on the potential impact on patient access to innovative medicines from the introduction of VAT to medicines provided free under Early Access Medicines S
Answer: VAT is the UK’s second largest tax, forecast to raise £180 billion in 2025/26. Taxation is a vital source of revenue which helps to fund public services. Early Access to Medicines Scheme (EAMS) allows patients access to free medicines for life threatening...
Answered 5 Nov 2025
Original Parliament recordBusiness: InvestmentTreasuryTabled 27 Oct 2025AnsweredUIN 85287More
Question: To ask the Chancellor of the Exchequer, whether she plans to expand the (a) Enterprise Investment Scheme and (b) Seed Enterprise Investment Scheme scheme to support older companies seeking increased investment.
Answer: The Government is focused on making the UK the best place in the world to start and grow a business, and understands the key role of a competitive investment environment in achieving economic growth. At Autumn Budget 2024, the Government committed to crea...
Answered 4 Nov 2025
Original Parliament recordBusiness: InvestmentTreasuryTabled 27 Oct 2025AnsweredUIN 85286More
Question: To ask the Chancellor of the Exchequer, what assessment her Department has made of the potential merits of reforming the (a) Enterprise Investment Scheme and (b) Seed Enterprise Investment Scheme to improve support for firms in the post-start-up phase.
Answer: The Government is focused on making the UK the best place in the world to start and grow a business, and understands the key role of a competitive investment environment in achieving economic growth. At Autumn Budget 2024, the Government committed to crea...
Answered 4 Nov 2025
Original Parliament recordCompanies: InvestmentDepartment for Business and TradeTabled 27 Oct 2025AnsweredUIN 85285More
Question: To ask the Secretary of State for Business and Trade, if he will make an assessment with the Chancellor of the Exchequer of the potential merits of creating a dedicated scale-up investment scheme.
Answer: The Chancellor and Secretary of State wrote on 20 October to the British Business Bank, setting the Bank’s strategic priorities over the next five years. These include an objective to “support our most promising businesses in the Industrial Strategy prior...
Answered 30 Oct 2025
Original Parliament recordTechnology: FinanceDepartment for Science, Innovation and TechnologyTabled 27 Oct 2025AnsweredUIN 85284More
Question: To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to support access to growth capital for scaling UK tech firms.
Answer: DSIT delivers specific policy interventions to unlock growth investment for UK science and technology firms, as well as contributing deep science and technology expertise to initiatives led by others, such as the British Business Bank’s £4bn Industrial St...
Answered 30 Oct 2025
Original Parliament recordMedical Treatments: VATDepartment for Science, Innovation and TechnologyTabled 23 Oct 2025AnsweredUIN 84784More
Question: To ask the Secretary of State for Science, Innovation and Technology, whether he has had recent discussions with the Chancellor of the Exchequer on the application of VAT for (a) medicines and (b) treatments provided for medical (i) trials or (ii) compass
Answer: The DSIT Secretary of State has not met with the Chancellor of the Exchequer to discuss this particular matter.There has been no recent law or policy change in this area.Application of VAT is determined on a case-by-case basis depending on specific detail...
Answered 30 Oct 2025
Original Parliament recordDrugs: VATTreasuryTabled 23 Oct 2025AnsweredUIN 84783More
Question: To ask the Chancellor of the Exchequer, if she will take steps with HM Revenue and Customs to help ensure that a(a) medicines and (b) treatments provided under the Early Access to Medicines Scheme are not subjected to (i) direct or (ii) indirect VAT.
Answer: VAT is the UK’s second largest tax, forecast to raise £180 billion in 2025/26. Taxation is a vital source of revenue which helps to fund public services. Early Access to Medicines Scheme (EAMS) allows patients access to free medicines for life threatening...
Answered 29 Oct 2025
Original Parliament recordDrugs: VATTreasuryTabled 23 Oct 2025AnsweredUIN 84781More
Question: To ask the Chancellor of the Exchequer, if she will commission guidance from HM Revenue and Customs clarifying whether medicines supplied under the Early Access Medicines Scheme fall outside the scope of VAT Deemed Supply rules.
Answer: Under UK VAT law, some transactions where no money changes hands are treated as if a supply has been made – these are called deemed supplies. This is to keep the system fair if a business has reclaimed VAT on costs (like making or importing goods), it sho...
Answered 29 Oct 2025
Original Parliament recordDrugs: VATTreasuryTabled 23 Oct 2025AnsweredUIN 84780More
Question: To ask the Chancellor of the Exchequer, whether medicines provided free under Early Access Medicines Scheme programmes are liable for output VAT.
Answer: Early Access to Medicines Scheme (EAMS) allows patients access to free medicines for life threatening conditions before receiving full NHS approval. There are special VAT rules for the supply of goods without payment. Whether VAT applies will depend on th...
Answered 29 Oct 2025
Original Parliament recordTelecommunications: Products and InfrastructureDepartment for Science, Innovation and TechnologyTabled 10 Oct 2025AnsweredUIN 78446More
Question: To ask the Secretary of State for Science, Innovation and Technology, what her Department's planned timetable is for the implementation of outstanding provisions in the Product Security and Telecommunications Infrastructure Act 2022.
Answer: As set out in the Written Ministerial Statement [made by the former Minister for Data Protection and Telecoms], we intend to implement the remaining provisions of the Product Security and Telecommunications Infrastructure Act 2022 as soon as possible. Sub...
Answered 15 Oct 2025
Original Parliament record
Published records only — not a full account of an MP’s work. How we work →